Knowledge-Based Artificial Intelligence System for Drug Prioritization

In silico drug prioritization may be a promising and time-saving strategy to identify potential drugs, standing as a faster and more cost-effective approach than de novo approaches. In recent years, artificial intelligence has greatly evolved the drug development process. Here, we present a novel computational framework for drug prioritization, labyrinth, designed to simulate human knowledge retrieval and inference to identify potential drug candidates for each disease. With the integration of up-to-date clinical trials, literature co-occurrences, drug–target interactions, and disease similarities, our framework achieves over 90% predictive accuracy across clinical trial phases and strong alignment with clinical practice in TCGA cohorts. We have demonstrated effectiveness across 20 different disease categories with robust ROC-AUC metrics and the balance between predictive accuracy and model interpretability. We further demonstrate its effectiveness at both the population and the individual levels. This study not only demonstrates the capacity for its drug prioritization but underscores the importance of aligning computational models with intuitive human reasoning. We have wrapped the core function into an R package named labyrinth, which is freely available on GitHub under the GPL-v2 license (https://github.com/hanjunwei-lab/labyrinth).This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Chemical Information and Modeling, copyright ©, [include copyright notice from the published article] after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles on Request author-directed link to Published Work, see ACS Articles on Request ].". Deposited by shareyourpaper.org and openaccessbutton.org. We've taken reasonable steps to ensure this content doesn't violate copyright. However, if you think it does you can request a takedown by emailing [email protected].